经会阴MRI融合靶向穿刺每病灶三针可有效检出临床显著前列腺癌
该前瞻性研究纳入101例至少有一个PI-RADS≥3病灶的患者,行经会阴MRI超声融合靶向穿刺(每病灶至少4针)后接系统穿刺,以≥4针为参考标准,发现每病灶3针与≥4针检出临床显著前列腺癌的一致性极高(Kappa 0.961),灵敏度95.2%,仅漏诊3个病灶。
要点
- 每病灶3针靶向穿刺与≥4针检出临床显著前列腺癌高度一致(Kappa 0.961)。
- 3针方案灵敏度95.2%(95%CI 85.8-98.8),仅漏诊3个临床显著前列腺癌病灶。
- PI-RADS 3或4或最大径<1.5 cm病灶同样适用3针策略。
核心结论
- 经会阴MRI超声融合靶向穿刺每病灶3针足以有效检出临床显著前列腺癌,尤其适用于PI-RADS 3或4或最大径<1.5 cm的病灶。
研究设计与样本
- 前瞻性研究,纳入101例至少有一个PI-RADS评分≥3病灶的患者。
- 每病灶至少行4针经会阴MRI超声融合靶向穿刺,随后行系统穿刺。
- 以≥4针靶向穿刺为参考标准,用Kappa检验评价不同针数与参考标准检出率的一致性。
主要发现
- 101例中系统穿刺、靶向穿刺、靶向联合系统穿刺检出临床显著前列腺癌分别为49例(48.5%)、55例(54.5%)、57例(56.4%)。
- 161个病灶中,基于1、2、3、≥4针靶向穿刺的临床显著前列腺癌检出率分别为27.3%、32.9%、37.3%、39.1%。
- 3针与≥4针检出临床显著前列腺癌一致性高(Kappa系数0.961,p<0.001),灵敏度95.2%(95%CI 85.8-98.8),仅漏诊3个临床显著前列腺癌病灶。
- PI-RADS 3或4或最大径<1.5 cm的病例获得相似结果。
关键数值与推荐
- PI-RADS评分≥3定义为至少1个病灶。
- 参考标准为每病灶≥4针靶向穿刺。
- 3针靶向穿刺与≥4针的Kappa系数0.961(p<0.001),灵敏度95.2%(95%CI 85.8-98.8)。
临床怎么用
- 经会阴MRI超声融合靶向穿刺时,每病灶可考虑3针以检出临床显著前列腺癌。
- 对PI-RADS 3或4或最大径<1.5 cm的病灶,3针策略尤其适用,有助于个体化穿刺方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this study we determined the optimal number of transperineal magnetic resonance imaging ultrasound fusion targeted biopsy cores per lesion needed for the detection of clinically significant prostate cancer. MATERIALS AND METHODS: A total of 101 patients with at least 1 lesion with a PI-RADS® (Prostate Imaging Reporting and Data System) score of 3 or greater were recruited prospectively. At least 4 transperineal magnetic resonance imaging ultrasound fusion targeted biopsy cores per lesion were performed, followed by systematic biopsy. The Kappa test was used to evaluate the consistency of the clinically significant prostate cancer detection rate between different targeted biopsy cores and 4 or more cores, which was regarded as reference standard. RESULTS: In the total cohort of 101 patients 49 (48.5%), 55 (54.5%) and 57 (56.4%) were diagnosed with clinically significant prostate cancer by systematic biopsy, targeted biopsy or targeted biopsy plus systematic biopsy, respectively. As for the total of 161 lesions, the clinically significant prostate cancer detection rate based on 1, 2, 3, or 4 or more targeted biopsy cores was made in 27.3%, 32.9%, 37.3% and 39.1%, respectively. Three cores showed great consistency with 4 or more cores in clinically significant prostate cancer detection rate (Kappa coefficient of 0.961, p <0.001) with a sensitivity of 95.2% (95% CI 85.8-98.8), and only missed 3 lesions harboring clinically significant prostate cancer. Similar results were obtained in cases with PI-RADS 3 or 4 or maximal diameter of less than 1.5 cm. CONCLUSIONS: Three targeted biopsies per lesion were suitable during transperineal magnetic resonance imaging ultrasound fusion biopsy, especially for lesions of PI-RADS 3 or 4, or small lesions (maximal diameter less than 1.5 cm), which may help to tailor targeted prostate biopsy procedures.
引用
- Song G, Ruan M, Wang H, et al. How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy? J Urol. 2020. PMID: 32716686. doi:10.1097/JU.0000000000001302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。